5FA Stock Chart & Stats
€8.35
€0.00(0.00%)
At close: 4:00 PM EST
€8.35
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€7.50 - €9.25
Previous CloseN/A
Volume0.00
Average Volume (3M)58.00
Market Cap
€1.38B
Enterprise Value€903.22K
Total Cash (Recent Filing)€104.86B
Total Debt (Recent Filing)€661.52B
Price to Earnings (P/E)17.8
Beta0.15
Next Earnings
Nov 05, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)86.21
Shares Outstanding171,459,470
10 Day Avg. Volume175
30 Day Avg. Volume58
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.92
Price to Sales (P/S)0.38
P/FCF Ratio-32.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.16Price Target Upside9.76% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.5
Revenue Forecast (FY)€3.79B
Bulls Say, Bears Say
Bulls Say
Steady Revenue ExpansionSustained top-line expansion indicates growing demand across Nipro’s medical-device, pharmaceutical-packaging, and manufacturing businesses, supporting scale and providing a durable base for future operating improvements.
Improving Operating MarginThe year-over-year margin improvement suggests better operating leverage or execution. If maintained, stronger operating profitability could improve earnings resilience and partially offset the company’s financing and investment demands.
Recurring Healthcare DemandDialysis-related products, hospital supplies, and pharmaceutical packaging benefit from repeat purchases and chronic-care needs. These recurring, healthcare-linked revenue streams can provide greater durability than discretionary industrial demand.
Bears Say
High Balance-Sheet LeverageDebt remains materially higher than equity despite improvement from FY2021. This leverage reduces financial flexibility, increases sensitivity to weaker margins or higher funding costs, and may constrain investment or shareholder returns.
Persistent Negative Free Cash FlowRepeated free-cash outflows indicate that operating cash generation has not covered investment and working-capital needs. This limits cash available for debt reduction and increases reliance on financing while leverage remains elevated.
Thin And Volatile ProfitabilityAlthough operating profit improved, bottom-line margins remain low and have fluctuated considerably. Limited earnings conversion leaves less buffer against cost increases, execution issues, or financing pressure across the business.
Nipro News
5FA FAQ
What was Nipro Corporation’s price range in the past 12 months?
Nipro Corporation lowest stock price was €7.50 and its highest was €9.25 in the past 12 months.
What is Nipro Corporation’s market cap?
Nipro Corporation’s market cap is €1.38B.
When is Nipro Corporation’s upcoming earnings report date?
Nipro Corporation’s upcoming earnings report date is Nov 05, 2026 which is in 68 days.
How were Nipro Corporation’s earnings last quarter?
Nipro Corporation released its earnings results on Aug 10, 2026. The company reported €0.127 earnings per share for the quarter, beating the consensus estimate of €0.078 by €0.049.
Is Nipro Corporation overvalued?
According to Wall Street analysts Nipro Corporation’s price is currently Undervalued.
Does Nipro Corporation pay dividends?
Nipro Corporation does not currently pay dividends.
What is Nipro Corporation’s EPS estimate?
Nipro Corporation’s EPS estimate is 0.11.
How many shares outstanding does Nipro Corporation have?
Nipro Corporation has 171,459,470 shares outstanding.
What happened to Nipro Corporation’s price movement after its last earnings report?
Nipro Corporation reported an EPS of €0.127 in its last earnings report, beating expectations of €0.078. Following the earnings report the stock price went up 0.578%.
Which hedge fund is a major shareholder of Nipro Corporation?
Currently, no hedge funds are holding shares in DE:5FA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nipro Corporation
Nipro Corporation, along with its affiliated companies, operates across three primary business divisions: medical devices, pharmaceuticals, and pharmaceutical packaging. The company's Medical Device sector is dedicated to the development, production, and distribution of an extensive selection of disposable medical products. These offerings encompass specialized items for renal treatment, interventional procedures and anesthesia, injection and infusion therapies, dialysis, cardiopulmonary support, diabetes management, and cell culture applications. This division also markets products associated with artificial organs, as well as generic and kit-based medical supplies. Within its Pharmaceutical division, Nipro delivers innovative pharmaceutical combination products, such as dual chamber bags, pre-filled syringes, and half-type kits. It further extends its services through contract manufacturing for orally administered medications, injectable solutions, and topical preparations. The Pharma Packaging segment is focused on providing a comprehensive array of glass packaging solutions. This includes vials, ampoules, syringes, cartridges, and glass tubes. Additionally, this division manufactures glass forming machinery, glass bulbs for vacuum flasks, and various other essential pharmaceutical packaging components, such as rubber stoppers. An 'Other' business activity involves the provision of thermostable enzymes, which are vital for clinical chemistry applications. Nipro also offers business management services. Established in Osaka, Japan, in 1947, Nipro Corporation now serves a wide international customer base, spanning Japan, the Americas, Europe, and other regions across Asia.
5FA Stock 12 Month Forecast
Average Price Target
€9.16
▲(9.76% Upside)







